What is Access Vascular?
Founded in 2015, Access Vascular specializes in the development and manufacturing of next-generation catheters designed to mitigate common complications associated with intravenous therapy. By leveraging advanced bio-materials, the company addresses critical clinical challenges such as catheter-related thrombosis and phlebitis. Positioned at the intersection of material science and interventional medicine, Access Vascular has transitioned from its early-stage development phase into a robust enterprise-level entity. Its product portfolio is engineered to enhance the safety and efficacy of vascular access, providing healthcare providers with durable, high-performance tools that reduce the frequency of device replacement and associated healthcare costs.
How much funding has Access Vascular raised?
Access Vascular has raised a total of $51.7M across 4 funding rounds:
Series A
$3.7M
Unspecified
$6M
Series B
$20M
Series C
$22M
Series A (2017): $3.7M with participation from angelMD
Unspecified (2019): $6M, investors not publicly disclosed
Series B (2021): $20M supported by TVM Capital GmbH
Series C (2023): $22M, investors not publicly disclosed
Key Investors in Access Vascular
angelMD
A specialized investment platform and community that connects medical startups with a network of physicians and healthcare industry experts.
TVM Capital GmbH
A venture capital firm with a long-standing history of investing in life sciences, healthcare, and medical technology companies across Europe and North America.
Undisclosed Investor
A strategic partner participating in the latest funding round to support the company's enterprise-level scaling objectives.
What's next for Access Vascular?
With the successful closure of its latest financing round, Access Vascular is well-positioned to scale its commercial operations and deepen its penetration into the global medical device market. The strategic allocation of this capital will likely focus on expanding manufacturing capacity, accelerating clinical research initiatives, and broadening the distribution network for its flagship catheter products. As the company moves into this next phase of growth, the focus will remain on securing regulatory milestones and establishing long-term partnerships with major hospital systems. By maintaining its commitment to bio-material innovation, Access Vascular is poised to set new standards in vascular care, potentially capturing significant market share from traditional catheter manufacturers while improving the standard of care for patients requiring long-term intravenous access.
See full Access Vascular company page
